Try our Advanced Search for more refined results
January 15, 2014
KBC Asset Management NV et al v. Aegerion Pharmaceuticals, Inc. et al
Case Number:
1:14-cv-10105
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Block & Leviton
- Fisher Potter
- Hogan Lovells
- Hutchings Barsamian
- Motley Rice
- Nutter McClennen
- Robbins Geller
- Ropes & Gray
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
December 07, 2017
Attys Get $4.5M Of $22M Aegerion Drug Marketing Settlement
A Massachusetts federal judge on Wednesday awarded $4.45 million in fees to attorneys who secured a $22.25 million settlement to end an investor class action accusing Aegerion Pharmaceuticals Inc. of hiding from shareholders the off-label marketing of the cholesterol drug Juxtapid.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login